**Chen 2013** Y Chen, W Zhang, WH Huang, ZR Tan, YC Wang, X Huang, HH Zhou (2013). Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. *Eur J Clin Pharmacol.*, Nov;69(11):1933-8.

**Cho 2024** CK Cho, JY Mo, E Ko, P Kang, CG Jang, SY Lee, YJ Lee, JW Bae, CI Choi  (2024). Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism. *Arch Pharm Res.*, Feb;47(2):95-110.

**Duan 2017** P Duan, P Zhao, L Zhang (2017). Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). *Eur J Drug Metab Pharmacokinet.* Aug;42(4):689-705.

**Ieiri 2007** Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin *Pharmacol Ther.* 2007 Nov;82(5):541-7

**Kimoto 2022** E Kimoto, C Costales, MA West, YA Bi, M Vourvahis, A David Rodrigues, MVS Varma (2022). Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions. *Clin Pharmacol Ther*, Feb;111(2):404-415.

**Lou 2015** Z Luo, Y Zhang, J Gu, P Feng, Y Wang (2015). Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. *Curr Ther Res Clin Exp*, Mar 3;77:52-7.

**Meyer 2012** Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. (2012). Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. *Drug Metab Dispos*. May;40(5), 892-901.

**Mochizuki 2022** T Mochizuki, Y Aoki, T Yoshikado, K Yoshida, Y Lai, H Hirabayashi, Y Yamaura, K Rockich, K Taskar, T Takashima, X Chu, MJ Zamek-Gliszczynski, J Mao, K Maeda, K Furihata, Y Sugiyama, H Kusuhara (2022). Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. *Clin Transl Sci.* Jun;15(6):1519-1531. 

**Mori 2020** D Mori, E Kimoto, B Rago, Y Kondo, A King‐Ahmad, R Ramanathan, LS Wood, JG Johnson, VH Le, M Vourvahis, A David Rodrigues (2020). Dose‐dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs. *Clinical Pharmacology & Therapeutics*, Apr;107(4):1004-13.

**Nishimura 2003** Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Yakugaku Zasshi.* May;123(5), 369-75.

**Prasad 2013** Prasad B, Lai Y, Lin Y, Unadkat JD (2013) Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. Journal of pharmaceutical sciences 102(3):787–93

**Prasad 2014** Prasad B, Evers R, Gupta A, Hop CECA, Salphati L, Shukla S, Ambudkar SV, Unadkat JD (2014) Interindividual variability in hepatic organic anion-transporting polypeptides and P-Glycoprotein (ABCB1) protein expression: Quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metabolism and Disposition 42(1):78–88

**Prueksaritanont 2014**T Prueksaritanont, X Chu, R Evers, SO Klopfer, L Caro, PA Kothare, C Dempsey, S Rasmussen, R Houle, G Chan, X Cai, R Valesky, IP Fraser, SA Stoch (2014). Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol., Sep;78(3):587-98.

**Takehara 2018** I Takehara, T Yoshikado, K Ishigame, D Mori, KI Furihata, N Watanabe, O Ando, K Maeda, Y Sugiyama, H Kusuhara (2018). Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers. *Pharmaceutical research*, Jul;35:1-3.



